Search - tctmd.com

Displaying 1 - 2 of 2

Sort: Relevancy | Date

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Industry News

CHMP grants positive opinion for idarucizumab, the specific reversal agent for dabigatran etexilate (Pradaxa®)

September 25, 2015

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.